EMEA-001207-PIP01-11-M01
Key facts
| Invented name |
Gazyvaro
|
| Active substance |
Obinutuzumab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0196/2021
|
| PIP number |
EMEA-001207-PIP01-11-M01
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Roche Registration GmbH
E-mail: info.paediatrics@roche.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|